UCB PHARMA SA
- Country
- 🇧🇪Belgium
- Ownership
- Public, Subsidiary
- Established
- 1928-01-01
- Employees
- 9K
- Market Cap
- $34.9B
Clinical Trials
270
Trial Phases
5 Phases
Drug Approvals
35
Drug Approvals
Certolizumab Pegol Injection
- Product Name
- 希敏佳
- Approval Number
- 国药准字SJ20190031
- Approval Date
- Aug 8, 2024
- Prev
- 1
- 2
- 3
- Next
Clinical Trials
Distribution across different clinical trial phases (247 trials with phase data)• Click on a phase to view related trials
A Brain Imaging Study With Positron Emission Tomography and the Radiotracer [11C]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam Enter the Brain in Healthy Volunteers
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2015-11-11
- Last Posted Date
- 2017-10-30
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 13
- Registration Number
- NCT02602860
- Locations
- 🇺🇸
Ep0074 001, New Haven, Connecticut, United States
A Study of Certolizumab Pegol to Evaluate Pharmacokinetics and Safety in Adult Healthy Chinese Subjects
- Conditions
- Healthy Subjects
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2015-08-14
- Lead Sponsor
- UCB Pharma SA
- Target Recruit Count
- 36
- Registration Number
- NCT02365948
- Locations
- 🇨🇳
1, Shanghai, China
An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044
- First Posted Date
- 2014-12-18
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- UCB Pharma SA
- Target Recruit Count
- 347
- Registration Number
- NCT02319642
- Locations
- 🇨🇳
037, Baotou, China
🇨🇳001, Beijing, China
🇨🇳002, Beijing, China
Study to Assess Safety, Tolerability, Pharmacokinetic & Pharmacodynamic Effect of UCB5857 in Healthy & Psoriatic Subject
- Conditions
- Psoriasis
- Interventions
- Drug: UCB5857 Part 1Drug: UCB5857 Part 2Other: Placebo
- First Posted Date
- 2014-12-01
- Last Posted Date
- 2014-12-01
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 57
- Registration Number
- NCT02303509
- Locations
- 🇬🇧
001, Harrow, United Kingdom
Single-site, Open-label, Randomized, Cross-over Study in Healthy Chinese Subjects to Evaluate the Bioequivalence of Single-dose Rotigotine Transdermal Patch Comparing 2 Different Formulations
- First Posted Date
- 2014-02-25
- Last Posted Date
- 2014-07-29
- Lead Sponsor
- UCB Pharma SA
- Target Recruit Count
- 50
- Registration Number
- NCT02070796
- Locations
- 🇨🇳
1, Hong Kong, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 54
- Next
News
New Global Review Reveals Comprehensive Landscape of Interstitial Cystitis Clinical Trials in 2025
• A newly released global clinical trials review provides extensive data on Interstitial Cystitis research, tracking trial numbers and enrollment trends across major countries worldwide. • The report categorizes trials by region, phase, status, and sponsorship, highlighting key pharmaceutical companies including Astellas Pharma, AbbVie, Johnson & Johnson, and Pfizer as prominent sponsors. • This comprehensive analysis serves as a strategic resource for stakeholders making investment decisions in IC research, offering insights into trial success rates and identifying optimal locations for clinical studies.
NHS Approves Fenfluramine for Children with Lennox-Gastaut Syndrome, Offering New Hope for Severe Epilepsy Treatment
The NHS has approved fenfluramine, the first non-cannabis based treatment for Lennox-Gastaut syndrome (LGS), offering new hope for children aged 2 and above with this severe form of epilepsy.
UCB Pharma Eyes Further Expansion in South Korea Following Recent Drug Approvals
UCB Pharma aims to expand its portfolio in South Korea after securing approvals for Bimzelx (bimekizumab) for plaque psoriasis and Zilbrysq (zilucoplan) for myasthenia gravis.
Bimekizumab Approved by FDA for Moderate to Severe Hidradenitis Suppurativa
The FDA has approved bimekizumab (Bimzelx; UCB Pharma) for treating moderate to severe hidradenitis suppurativa in adults, marking its fifth approved indication in the US.
FDA Approves Bimekizumab (Bimzelx) for Moderate-to-Severe Hidradenitis Suppurativa
The FDA has approved bimekizumab-bkzx (Bimzelx) for treating moderate-to-severe hidradenitis suppurativa (HS) in adult patients, addressing a significant unmet clinical need.
UCB's Bepranemab Shows Promise in Reducing Tau Tangles in Alzheimer's Subgroup
• Bepranemab, a monoclonal antibody from UCB Pharma, is the first to demonstrate a slowing of tau tangle accumulation in Alzheimer's patients, marking a potential shift in treatment strategies. • Phase 2 trial data suggests cognitive benefits in a subgroup with low baseline tau levels and without the ApoE4 mutation, indicating a targeted approach may be necessary for efficacy. • The trial results support the hypothesis that extracellular tau 'seeds' drive Alzheimer's progression, opening avenues for understanding disease mechanisms and developing combination therapies. • Several companies are developing antibodies targeting the microtubule binding region (MTBR) of tau, with ongoing trials exploring their impact on tau spread and clinical outcomes.
Certolizumab Pegol Reduces Inflammation in axSpA but Clinical Improvement Varies
A post hoc analysis of the RAPID-axSpA trial showed certolizumab pegol (CZP) significantly reduced inflammation in patients with axial spondyloarthritis (axSpA).
Rozanolixizumab Shows Efficacy in Older Adults with Generalized Myasthenia Gravis
A post-hoc analysis of the Phase 3 MycarinG study reveals rozanolixizumab's efficacy in treating generalized myasthenia gravis (gMG) in patients aged 65 and older.